Trial Profile

A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itacitinib (Primary) ; Axicabtagene ciloleucel; Tisagenlecleucel
Indications Cytokine release syndrome
Focus Therapeutic Use
Sponsors Incyte Corporation

Most Recent Events

12 Dec 2023 Preliminary Results (n=47) assessing Itacitinib for the Prevention of Immune Effector Cell Therapy Associated Cytokine Release Syndrome presented at the 65th American Society of Hematology Annual Meeting and Exposition
29 Aug 2023 Status changed from active, no longer recruiting to completed.
07 Aug 2023 Planned End Date changed from 22 Jul 2023 to 22 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com